NEUROCRINE BIOSCIENCES, INC.

Business Segments Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
128.13 ^USD	-1.16%		-3.12%	-9.66%

04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM
13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT

Sales 2025 by Business Segment

© MarketScreener.com See more

Sales 2025 by Geography

© MarketScreener.com See more

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment (USD)

Fiscal Period: December	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Biological Products
Research and Development, Commercialization, and Sale of Pharmaceuticals						113.35Cr	148.87Cr	188.71Cr	235.53Cr	286.05Cr
Total Assets						207.25Cr	236.87Cr	325.14Cr	371.87Cr	463.15Cr
Interest Expense						-2.58Cr	-71L	-46L	-	-
Income Tax Expense						1.18Cr	5.94Cr	8.24Cr	14Cr	23Cr
CAPEX						-2.34Cr	-1.65Cr	-2.83Cr	-3.82Cr	-3.4Cr
EBT						10Cr	21Cr	33Cr	49Cr	71Cr
D&A						1.09Cr	1.51Cr	2.13Cr	2.71Cr	3.01Cr
Operating Income						10Cr	25Cr	25Cr	57Cr	62Cr
Net Income						8.96Cr	15Cr	25Cr	34Cr	48Cr

Geographical Revenue Distribution History

Geographical breakdown of sales (USD)

Fiscal Period: December	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
United States						113.35Cr	148.87Cr	188.71Cr	235.53Cr	286.05Cr
Total Assets						207.25Cr	236.87Cr	325.14Cr	371.87Cr	463.15Cr
Interest Expense						-2.58Cr	-71L	-46L	-	-
Income Tax Expense						1.18Cr	5.94Cr	8.24Cr	14Cr	23Cr
D&A						1.09Cr	1.51Cr	2.13Cr	2.71Cr	3.01Cr
CAPEX						-2.34Cr	-1.65Cr	-2.83Cr	-3.82Cr	-3.4Cr
Net Income						8.96Cr	15Cr	25Cr	34Cr	48Cr
EBT						10Cr	21Cr	33Cr	49Cr	71Cr
Operating Income						10Cr	25Cr	25Cr	57Cr	62Cr

As early as today, start finding the best investment opportunities!